Eva Gizella Rakasz

Dr. Eva Gizella Rakasz

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
HTHannah L. Turner
Hannah L. Turner
RARaiees Andrabi
Raiees Andrabi
CCChristopher A. Cottrell
Christopher A. Cottrell
SRSara T. Richey
Sara T. Richey
GSGe Song
Ge Song
AWAndrew Ward
Andrew Ward
HIV Env trimers elicit antibodies that lead to their own destruction.

24 July 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MGMatthew Gardner
Matthew Gardner
CFChristoph H. Fellinger
Christoph H. Fellinger
LKLisa M. Kattenhorn
Lisa M. Kattenhorn
MDMeredith E. Davis-Gardner
Meredith E. Davis-Gardner
JWJesse A. Weber
Jesse A. Weber
MFMichael Farzan
Michael Farzan
A number of simian and simian human immunodeficiency viruses (SIV and SHIV, respectively) have been used to assess the efficacy of HIV-1 vaccine strategies. Among these, SIVmac239 is considered among the most stringent because, unlike SHIV models, its full genome has coevolved in its macaque host and its tier 3 envelope glycoprotein (Env) is exceptionally hard to neutralize. Here, we investigated the ability of eCD4-Ig, an antibody-like entry inhibitor that emulates the HIV-1 and SIV receptor and coreceptor, to prevent SIVmac239 infection. We show that rh-eCD4-IgI39N expressed by recombinant adeno-associated virus (AAV) vectors afforded four rhesus macaques complete protection from high-dose SIVmac239 challenges that infected all eight control macaques. However, rh-eCD4-IgI39N–expressing macaques eventually succumbed to serial escalating challenge doses that were 2, 8, 16, and 32 times the challenge doses that infected the control animals. Despite receiving greater challenge doses, these macaques had significantly lower peak and postpeak viral loads than the control group. Virus isolated from three of four macaques showed evidence of strong immune pressure from rh-eCD4-IgI39N, with mutations located in the CD4-binding site, which, in one case, exploited a point-mutation difference between rh-eCD4-IgI39N and rhesus CD4. Other escape pathways associated with clear fitness costs to the virus. Our data report effective protection of rhesus macaques from SIVmac239.

7 February 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MPMary S. Pampusch
Mary S. Pampusch
HAHadia M. Abdelaal
Hadia M. Abdelaal
ECEmily K. Cartwright
Emily K. Cartwright
JMJhomary S Molden
Jhomary S Molden
BDBrianna C. Davey
Brianna C. Davey
PSPamela Skinner
Pamela Skinner
During chronic human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) infection prior to AIDS progression, the vast majority of viral replication is concentrated within B cell follicles of secondary lymphoid tissues. We investigated whether infusion of T cells expressing an SIV-specific chimeric antigen receptor (CAR) and the follicular homing receptor, CXCR5, could successfully kill viral-RNA+cells in targeted lymphoid follicles in SIV-infected rhesus macaques. In this study, CD4 and CD8 T cells from rhesus macaques were genetically modified to express antiviral CAR and CXCR5 moieties (generating CAR/CXCR5-T cells) and autologously infused into a chronically infected animal. At 2 days post-treatment, the CAR/CXCR5-T cells were located primarily in spleen and lymph nodes both inside and outside of lymphoid follicles. Few CAR/CXCR5-T cells were detected in the ileum, rectum, and lung, and no cells were detected in the bone marrow, liver, or brain. Within follicles, CAR/CXCR5-T cells were found in direct contact with SIV-viral RNA+cells. We next infused CAR/CXCR5-T cells into ART-suppressed SIV-infected rhesus macaques, in which the animals were released from ART at the time of infusion. These CAR/CXCR5-T cells replicated in vivo within both the extrafollicular and follicular regions of lymph nodes and accumulated within lymphoid follicles. CAR/CXR5-T cell concentrations in follicles peaked during the first week post-infusion but declined to undetectable levels after 2 to 4 weeks. Overall, CAR/CXCR5-T cell-treated animals maintained lower viral loads and follicular viral RNA levels than untreated control animals, and no outstanding adverse reactions were noted. These findings indicate that CAR/CXCR5-T cell treatment is safe and holds promise as a future treatment for the durable remission of HIV.

17 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LHLars Hangartner
Lars Hangartner
DBDavid Beauparlant
David Beauparlant
EREva Gizella Rakasz
Eva Gizella Rakasz
RNRebecca Nedellec
Rebecca Nedellec
NHNathanaël Hozé
Nathanaël Hozé
DBDennis R. Burton
Dennis R. Burton
Effector function is not required for a potent HIV envelope–specific broadly neutralizing antibody to protect nonhuman primates from SHIV infection.

8 March 2024 in Science
Verified
Journal Article
Open access
SLSo-Yon Lim
So-Yon Lim
JLJina Lee
Jina Lee
COChrista E. Osuna
Christa E. Osuna
PVPratik Vikhe
Pratik Vikhe
DSDane R. Schalk
Dane R. Schalk
JWJames B. Whitney
James B. Whitney
The eradication of the viral reservoir represents the major obstacle to the development of a clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of N-803 (brand name Anktiva) and broadly neutralizing antibodies (bNAbs) results in sustained viral control after discontinuation of antiretroviral therapy (ART) in simian-human AD8 (SHIV-AD8)–infected, ART-suppressed rhesus macaques. N-803+bNAbs treatment induced immune activation and transient viremia but only limited reductions in the SHIV reservoir. Upon ART discontinuation, viral rebound occurred in all animals, which was followed by durable control in approximately 70% of all N-803+bNAb–treated macaques. Viral control was correlated with the reprogramming of CD8 + T cells by N-803+bNAb synergy. Thus, complete eradication of the replication-competent viral reservoir is likely not a prerequisite for the induction of sustained remission after discontinuation of ART.

14 July 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MRMoritz Ries
Moritz Ries
MRMatthew R Reynolds
Matthew R Reynolds
KBKsenia Bashkueva
Ksenia Bashkueva
KCKristin Crosno
Kristin Crosno
SCSaverio Capuano
Saverio Capuano
DEDavid T. Evans
David T. Evans
Natural killer cells provide an important early defense against viral pathogens and are regulated in part by interactions between highly polymorphic killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their MHC class I ligands on target cells. We previously identified MHC class I ligands for two rhesus macaque KIRs: KIR3DL01 recognizes Mamu-Bw4 molecules and KIR3DL05 recognizes Mamu-A1*002. To determine how these interactions influence NK cell responses, we infected KIR3DL01+ and KIR3DL05+ macaques with and without defined ligands for these receptors with SIVmac239, and monitored NK cell responses in peripheral blood and lymphoid tissues. NK cell responses in blood were broadly stimulated, as indicated by rapid increases in the CD16+ population during acute infection and sustained increases in the CD16+ and CD16-CD56- populations during chronic infection. Markers of proliferation (Ki-67), activation (CD69 & HLA-DR) and antiviral activity (CD107a & TNFα) were also widely expressed, but began to diverge during chronic infection, as reflected by sustained CD107a and TNFα upregulation by KIR3DL01+, but not by KIR3DL05+ NK cells. Significant increases in the frequency of KIR3DL01+ (but not KIR3DL05+) NK cells were also observed in tissues, particularly in the gut-associated lymphoid tissues, where this receptor was preferentially upregulated on CD56+ and CD16-CD56- subsets. These results reveal broad NK cell activation and dynamic changes in the phenotypic properties of NK cells in response to SIV infection, including the enrichment of KIR3DL01+ NK cells in tissues that support high levels of virus replication. Natural killer (NK) cells are an important cellular defense against viral pathogens, and are regulated in part by interactions between killer-cell immunoglobulin-like receptors (KIRs) on NK cells and MHC class I ligands on target cells. Using multi-parameter flow cytometry, we report the first longitudinal study of changes in the phenotypic and functional properties of NK cells in KIR- and MHC class I-defined rhesus macaques infected with simian immunodeficiency virus (SIV). Our findings reveal broad NK cell activation and highly dynamic changes in the phenotypic properties of NK cells in response to SIV infection, including an enrichment of NK cells expressing KIR3DL01 in tissues that represent sites of high levels of virus replication.